复方磺胺甲噁唑降低高危血液透析患者类鼻疽发病率
在澳大利亚北部类鼻疽流行区,对血液透析患者开展前瞻性干预研究,比较每日复方磺胺甲噁唑预防与不预防的效果。结果显示预防组类鼻疽发生率为0%,非预防组为17.4%(P<0.001),预防组血小板减少和中性粒细胞减少发生率更高但未导致停药,每日给药有效且安全。
要点
- 血液透析患者雨季每日复方磺胺甲噁唑预防可显著降低类鼻疽发生率。
- 预防组血小板减少和中性粒细胞减少更常见,但未需停药。
- 推荐在类鼻疽流行区对高危血液透析患者采用该预防策略。
核心结论
- 每日复方磺胺甲噁唑预防在血液透析患者中有效且安全,可降低类鼻疽发生率。
研究设计与样本
- 前瞻性干预研究,2014年11月1日至2015年4月30日雨季期间纳入269例维持性血液透析≥3个月、年龄≥18岁的患者,其中8例因正在接受类鼻疽治疗被排除,最终分析261例。
主要发现
- 261例中169例(64.8%)接受预防,92例(35.2%)未接受。
- 预防组类鼻疽发生率为0%(0/169),非预防组为17.4%(16/92),P<0.001。
- 预防组血小板减少和中性粒细胞减少发生率更高,但未导致治疗中止;肝功能无差异。
- 3例(1.8%)因副作用退出治疗。
临床怎么用
- 在类鼻疽流行区,可考虑对高危血液透析患者雨季每日给予复方磺胺甲噁唑预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Melioidosis causes sepsis and death in the Top End of Northern Australia during the monsoonal wet season. Dialysis-dependent adults suffer higher melioidosis rates compared to low rates among renal transplant patients who routinely receive trimethoprim+sulfamethoxazole prophylaxis. METHODS: We performed a prospective interventional study to determine the efficacy and safety of daily trimethoprim+sulfamethoxazole prophylaxis in hemodialysis patients during the wet season, from 1 November 2014 to 30 April 2015. Hemodialysis (for ≥ 3 months) patients ≥ 18 years of age were offered treatment. A total of 269 patients on hemodialysis were eligible. Eight of the 269 patients (3%) were excluded from the analysis for being on melioidosis treatment. In all, 169 of 261 patients (64.8%) received the prophylaxis, and 92 of 261 patients (35.2%) did not, because of allergy history (n = 10), remoteness and logistical reasons (n = 60), poor dialysis attendance (n = 11), and refusal (n = 11). We monitored for clinical side effects 3 times weekly and neutropenia, thrombocytopenia, and liver function monthly throughout treatment and for 2 months posttreatment. RESULTS: In all, 169 of 261 patients (64.8%) received the prophylaxis. There was no age (years) difference by group (prophylaxis vs. nonprophylaxis, 54.7 [11.3] vs. 54.3 [11.2] [P = 0.751]). Sixteen of 261 patients (6%) had melioidosis. The event frequency was 0% (0/169, prophylaxis, vs. 17.4% [16/92, nonprophylaxis], P < 0.001). Higher thrombocytopenia and neutropenia rates were noted in the prophylaxis group. These did not warrant treatment stoppage. There was no difference in liver function. Three patients (1.8%) withdrew from the treatment because of side effects. CONCLUSION: Daily dosing was effective and safe. Posthemodialysis dosing in the subsequent seasons was effective and safer. We recommend this approach in melioidosis-prevalent regions.
引用
- Majoni SW, Hughes JT, Heron B, et al. Trimethoprim+Sulfamethoxazole Reduces Rates of Melioidosis in High-Risk Hemodialysis Patients. Kidney Int Rep. 2017. PMID: 29340327. doi:10.1016/j.ekir.2017.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。